Tempus AI (NASDAQ:TEM) Trading 8.3% Higher on Analyst Upgrade

Tempus AI, Inc. (NASDAQ:TEM)’s share price rose 8.3% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $70.00 to $80.00. BTIG Research currently has a buy rating on the stock. Tempus AI traded as high as $72.62 and last traded at $72.21. 9,425,782 shares traded hands during mid-day trading, an increase of 58% from the average daily volume of 5,961,162 shares. The stock had previously closed at $66.65.

Several other equities analysts also recently commented on the company. HC Wainwright cut their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Guggenheim lifted their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and a consensus price target of $65.69.

Insider Transactions at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 132,591 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $6,577,839.51. Following the transaction, the chief executive officer directly owned 2,098,130 shares in the company, valued at approximately $104,088,229.30. This trade represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 6,175 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $306,341.75. Following the transaction, the chief accounting officer directly owned 67,866 shares in the company, valued at approximately $3,366,832.26. The trade was a 8.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 943,202 shares of company stock worth $46,417,587. Insiders own 24.26% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Investor enthusiasm has continued following reported progress in the Merck–Moderna cancer-vaccine program. Although the development is not directly attributable to Tempus, it reinforces the potential value of genomic data and precision-oncology platforms—areas central to Tempus’ strategy. Tempus AI stock move
• Positive Sentiment: BTIG Research raised its Tempus price target from $70 to $80 and maintained a “Buy” rating. The upgrade provides a fresh Wall Street catalyst and suggests analysts see additional upside after the recent advance. BTIG raises Tempus AI price target
• Positive Sentiment: Tempus’ planned approximately $1.5 billion all-stock acquisition of Personalis is attracting investor attention. The deal would add genomic-data and cancer-testing capabilities, potentially strengthening Tempus’ drug-development and precision-medicine platform. Tempus AI biotech deal
• Positive Sentiment: Trading activity has been supportive: call-option volume was reported at roughly 40,671 contracts, well above normal levels. That indicates bullish speculation and may be amplifying the stock’s momentum.
• Neutral Sentiment: The move above key moving averages has been characterized as a possible short squeeze. This can extend gains, but it also increases the risk of sharp reversals and continued volatility. Tempus AI technical rally
• Negative Sentiment: Several executives, including the CEO, CFO, EVP and chief accounting officer, sold shares. The transactions reduced their holdings, but were conducted under pre-arranged Rule 10b5-1 plans and were intended to cover tax obligations on vested equity awards, making them a relatively weak bearish signal.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently added to or reduced their stakes in TEM. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the third quarter valued at about $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI in the 4th quarter worth approximately $27,000. EMC Capital Management bought a new position in shares of Tempus AI during the 2nd quarter worth approximately $29,000. Harvest Fund Management Co. Ltd bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $38,000. Finally, Whittier Trust Co. lifted its position in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after acquiring an additional 570 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

The company has a market cap of $13.03 billion, a PE ratio of -50.15 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock’s 50-day moving average is $52.44 and its 200 day moving average is $51.21.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period in the prior year, the firm posted ($0.22) earnings per share. The business’s quarterly revenue was up 21.6% on a year-over-year basis. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.